Aer Therapeutics

About Aer Therapeutics

AER Therapeutics is focused on improving lung health by targeting mucus obstructions in chronic lung diseases. Their mission is to develop innovative therapies that clear mucus plugs, restore airflow, reduce inflammation, and enhance the effectiveness of other treatments for patients with conditions like COPD and asthma.

Products & Services

AER-01:An inhaled therapy designed to liquify mucus plugs by cleaving chemical bonds that thicken mucus, thereby opening airways, restoring airflow, reducing inflammation, and enabling other treatments to reach deeper into the lungs. It targets COPD and asthma patients.

Specialties

Muco-obstructive lung disease treatment Mucus-targeting therapies Inhaled therapies for COPD and asthma

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 36000000 MR: - FA: $36 million FAN: 36000000	D: 2023-04-13 FD: 2023-04-13	3 investors

Series A Latest

2023-04-13

$36.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Thomas P. Mathers

Executive Chairman and Interim CEO

LinkedIn (Pro only)

J

John Fahy, MD, MSc

Founder and Chief Clinical Consultant

LinkedIn (Pro only)

W

William Thelin, PhD

SVP, Drug Development

LinkedIn (Pro only)

B

Bernice Kuca

Head, Clinical and Regulatory Operations

I

Irina Gitlin, PhD

Vice President, Research and Development

B

Blair Capel

Senior Director, Finance and Administration

View 8 more team members with Pro

Unlock Full Team Directory

Recent News